US health agency ramps up AI use as transparency gaps persist
The US Department of Health and Human Services (HHS) has sharply expanded its use of artificial intelligence, listing around 450 AI use cases across the department in a newly published fiscal 2025 inventory.
The inventory, released by HHS’ technology office, shows AI tools in use or development across benefits processing, financial management, data extraction and computer vision, even as the agency operates with thousands fewer staff than a year ago.
Most use cases are classified as not high-impact, or as presumed high-impact but later downgraded, with many already deployed or in pilot stages. Only a small number are marked as retired, pointing to continued momentum behind AI adoption across HHS components.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze